Archive for the 'Vinorelbine' Category
September 5th, 2008. Systemic Treatments for Mesothelioma: Standard and Novel
These include drugs targeted against the epidermal growth factor, platelet-derived growth factor, vascular endothelial growth factor, src kinase, histone deacetylase, the proteasome, and mesothelin. Given the progress made in recent years, there is reason to believe that more effective treatments will continue to be developed.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, EGFR, Full Archive, Gemcitabine (Gemzar), General, Irinotecan, Kinase Inhibitors, New & Novel, Pemetrexed (Alimta), Raltitrexed (Tomudex), Staging, Treatment, Type of Assessment:, Vinorelbine | No Comments »
June 11th, 2008. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.
June 5th, 2008. Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine
Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion. He survived for 36 weeks, with symptom-free survival of 34 weeks.
Posted in Case Study, Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Epithelioid, Full Archive, Gemcitabine (Gemzar), Pleural, Pleural Biopsy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, thoracoscopy | No Comments »
May 20th, 2008. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
Weekly vinorelbine appeared to have a reasonable response rate with an acceptable toxicity profile in the second-line treatment of MPM. Its use should be prospectively evaluated in a randomised trial in the first or second-line therapy of MPM.
May 20th, 2008. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
Interpretation: The addition of chemotherapy to ASC offers no significant benefits in terms of overall survival or quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Pleural, Radiation, Survival, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, mitomycin-C | No Comments »
February 21st, 2008. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
Conclusions: The gemcitabine and vinorelbine combination was moderately active and had an acceptable toxicity profile in pemetrexed-pretreated patients with MPM. The role of second-line treatment in MPM needs to be evaluated in prospective trials in large series of patients who are stratified according to previous treatment and prognostic factors.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine | No Comments »
February 2nd, 2008. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice
Conclusions: Pemetrexed/cisplatin demonstrated acceptable cost-effectiveness when compared with cisplatin monotherapy and alternative treatments commonly used in UK clinical practice.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Pemetrexed (Alimta), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, mitomycin-C | No Comments »
December 6th, 2006. A case of malignant mesothelioma presenting with recurrent pneumothorax
The histological examination of the biopsied subcutaneous tumor showed mixed type malignant pleural mesothelioma. Chemotherapy with gemcitabine and vinorelbine could not control the progression.
March 13th, 2006. Triplet Chemotherapy for Malignant Pericardial Mesothelioma: A Case Report
The patient experienced no severe non-hematological or hematological toxicities except for grade 3 neutropenia. The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression.
Posted in Case Study, Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Full Archive, Gemcitabine (Gemzar), Pericardial, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine | No Comments »
December 14th, 2005. Mesothelioma: advances in chemotherapy
Some preliminary data from studies of second line chemotherapy is also available. Finally studies of targeted therapies such as anti-EGFR, anti VEGF and anti PDGF are underway but have not as yet demonstrated major therapeutic benefit.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, EGFR, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Raltitrexed (Tomudex), Treatment, Type of Assessment:, Vinorelbine | No Comments »
July 1st, 2005. Prognostic factors in mesothelioma
3] for those in the worst group. The suggestion is that all clinical and biological factors relevant to prognosis should be recorded prospectively in mesothelioma patients selected for clinical trials.
|
|  |
